Q-omics provides the consensus-scored PHF21A profile across patient tissues and cancer cell-line models. PHF21A expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, PHF21A is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, PHF21A RNA expression shows 21,005 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and KIRC as cancer lineages where PHF21A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PHF21A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PHF21A survival associations across molecular data types. PHF21A RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PHF21A RNA expression–survival associations across cancer types. High PHF21A expression shows unfavorable associations in ACC, LIHC and COAD, but favorable associations in SKCM, BRCA and HNSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for PHF21A RNA expression.
This table summarizes PHF21A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PHF21A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PHF21A shows lower tumor expression in UCEC and BRCA and higher tumor expression in KIRC, LIHC, HNSC and CHOL. The KIRC box plot shows higher PHF21A RNA expression in tumor versus normal tissue (log2 FC = +0.747, t-test p < 0.001).
This table shows molecular features associated with PHF21A in patient tissues and cancer cell lines. In patient samples, PHF21A shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, PHF21A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in CNS and UPPER_AERODIGESTIVE_TRACT.
